Influenza Vaccines

"Influenza Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more INFLUENZAVIRUS A and INFLUENZAVIRUS B strains.

Descriptor ID	D007252
MeSH Number(s)	D20.215.894.899.302
Concept/Terms	Influenza Vaccines Influenza Vaccines Influenza Vaccine Vaccine, Influenza Flu Vaccines Influenzavirus Vaccines Influenza Virus Vaccines Influenza Virus Vaccine Vaccine, Influenza Virus Virus Vaccine, Influenza High-Dose Trivalent Influenza Vaccine High-Dose Trivalent Influenza Vaccine High Dose Trivalent Influenza Vaccine Monovalent Influenza Vaccines Monovalent Influenza Vaccines Influenza Vaccines, Monovalent Vaccines, Monovalent Influenza Trivalent Influenza Vaccine Trivalent Influenza Vaccine Influenza Vaccine, Trivalent Vaccine, Trivalent Influenza Intranasal Live-Attenuated Influenza Vaccine Intranasal Live-Attenuated Influenza Vaccine Intranasal Live Attenuated Influenza Vaccine Universal Flu Vaccines Universal Flu Vaccines Universal Influenza Vaccines Trivalent Live Attenuated Influenza Vaccine Trivalent Live Attenuated Influenza Vaccine LAIV Vaccine Vaccine, LAIV Quadrivalent Influenza Vaccine Quadrivalent Influenza Vaccine Influenza Vaccine, Quadrivalent Vaccine, Quadrivalent Influenza

Below are MeSH descriptors whose meaning is more general than "Influenza Vaccines".

Chemicals and Drugs [D]
Complex Mixtures [D20]
Biological Products [D20.215]
Vaccines [D20.215.894]
Viral Vaccines [D20.215.894.899]
Influenza Vaccines [D20.215.894.899.302]

Below are MeSH descriptors whose meaning is more specific than "Influenza Vaccines".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Influenza Vaccines" by people in this website by year, and whether "Influenza Vaccines" was a major or minor topic of these publications.

Bar chart showing 59 publications over 21 distinct years, with a maximum of 8 publications in 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1998	2	0	2
1999	1	0	1
2001	0	1	1
2003	2	1	3
2004	2	0	2
2006	1	1	2
2007	2	0	2
2008	6	0	6
2009	1	0	1
2011	2	1	3
2012	1	0	1
2013	2	0	2
2014	1	0	1
2015	1	0	1
2016	3	3	6
2017	1	1	2
2018	3	0	3
2019	1	1	2
2020	3	0	3
2021	4	3	7
2022	8	0	8

Below are the most recent publications written about "Influenza Vaccines" by people in Profiles.

Turbyfill C, Adams K, Tenforde MW, Murray NL, Gaglani M, Ginde AA, McNeal T, Ghamande S, Douin DJ, Keipp Talbot H, Casey JD, Mohr NM, Zepeski A, Shapiro NI, Gibbs KW, Clark Files D, Hager DN, Shehu A, Prekker ME, Frosch AE, Exline MC, Gong MN, Mohamed A, Johnson NJ, Srinivasan V, Steingrub JS, Peltan ID, Brown SM, Martin ET, Lauring AS, Khan A, Busse LW, Ten Lohuis CC, Duggal A, Wilson JG, June Gordon A, Qadir N, Chang SY, Mallow C, Rivas C, Kwon JH, Halasa N, Chappell JD, Grijalva CG, Rice TW, Stubblefield WB, Baughman A, Rhoads JP, Lindsell CJ, Hart KW, McMorrow M, Surie D, Self WH, Patel MM. Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States. Vaccine. 2022 11 15; 40(48):6979-6986.

View in: PubMed
Seaman MS, Siedner MJ, Boucau J, Lavine CL, Ghantous F, Liew MY, Mathews JI, Singh A, Marino C, Regan J, Uddin R, Choudhary MC, Flynn JP, Chen G, Stuckwisch AM, Lipiner T, Kittilson A, Melberg M, Gilbert RF, Reynolds Z, Iyer SL, Chamberlin GC, Vyas TD, Vyas JM, Goldberg MB, Luban J, Li JZ, Barczak AK, Lemieux JE. Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variant. JCI Insight. 2022 10 10; 7(19).

View in: PubMed
Lewis NM, Self WH, Gaglani M, Ginde AA, Douin DJ, Keipp Talbot H, Casey JD, Mohr NM, Zepeski A, Ghamande SA, McNeal TA, Shapiro NI, Gibbs KW, Files DC, Hager DN, Shehu A, Prekker ME, Erickson HL, Gong MN, Mohamed A, Johnson NJ, Srinivasan V, Steingrub JS, Peltan ID, Brown SM, Martin ET, Monto AS, Khan A, Busse LW, Lohuis CCT, Duggal A, Wilson JG, Gordon AJ, Qadir N, Chang SY, Mallow C, Rivas C, Babcock HM, Kwon JH, Exline MC, Lauring AS, Halasa N, Chappell JD, Grijalva CG, Rice TW, Rhoads JP, Jones ID, Stubblefield WB, Baughman A, Womack KN, Lindsell CJ, Hart KW, Zhu Y, Adams K, Patel MM, Tenforde MW. Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States. Clin Infect Dis. 2022 10 03; 75(Suppl 2):S159-S166.

View in: PubMed
Fisher L, Loiacono MM, Payne N, Kelley T, Greenberg M, Charpentier M, Leblanc C, Sundaresan D, Bancroft T, Steffens A, Paudel M. A novel household-based patient outreach pilot program to boost late-season influenza vaccination rates during the COVID-19 pandemic. Influenza Other Respir Viruses. 2022 11; 16(6):1141-1150.

View in: PubMed
Kugler-Umana O, Zhang W, Kuang Y, Liang J, Castonguay CH, Tonkonogy SL, Marshak-Rothstein A, Devarajan P, Swain SL. IgD+ age-associated B cells are the progenitors of the main T-independent B cell response to infection that generates protective Ab and can be induced by an inactivated vaccine in the aged. Aging Cell. 2022 10; 21(10):e13705.

View in: PubMed
Desalermos A, Pimienta M, Kalligeros M, Shehadeh F, Diamantopoulos L, Karamanolis G, Caldera F, Farraye FA. Safety of Immunizations for the Adult Patient With Inflammatory Bowel Disease-A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2022 09 01; 28(9):1430-1442.

View in: PubMed
Dhume K, Finn CM, Devarajan P, Singh A, Tejero JD, Prokop E, Strutt TM, Sell S, Swain SL, McKinstry KK. Bona Fide Th17 Cells without Th1 Functional Plasticity Protect against Influenza. J Immunol. 2022 04 15; 208(8):1998-2007.

View in: PubMed
Devarajan P, Vong AM, Castonguay CH, Kugler-Umana O, Bautista BL, Jones MC, Kelly KA, Xia J, Swain SL. Strong influenza-induced TFH generation requires CD4 effectors to recognize antigen locally and receive signals from continuing infection. Proc Natl Acad Sci U S A. 2022 02 22; 119(8).

View in: PubMed
Feldstein LR, Ferdinands JM, Self WH, Randolph AG, Aboodi M, Baughman AH, Brown SM, Exline MC, Clark Files D, Gibbs K, Ginde AA, Gong MN, Grijalva CG, Halasa N, Khan A, Lindsell CJ, Newhams M, Peltan ID, Prekker ME, Rice TW, Shapiro NI, Steingrub J, Talbot HK, Halloran ME, Patel M. Modeling the Impacts of Clinical Influenza Testing on Influenza Vaccine Effectiveness Estimates. J Infect Dis. 2021 12 15; 224(12):2035-2042.

View in: PubMed
Swain SL, Jones MC, Devarajan P, Xia J, Dutton RW, Strutt TM, McKinstry KK. Durable CD4 T-Cell Memory Generation Depends on Persistence of High Levels of Infection at an Effector Checkpoint that Determines Multiple Fates. Cold Spring Harb Perspect Biol. 2021 11 01; 13(11).

View in: PubMed

People

Explore

Similar Concepts

Top Journals